Tradestie Institutional Equity Comparison Engine
ENTX vs CING โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ENTX Overall Edge
ENTX Captures Institutional Edge (2โ0 Pillars ยท 5โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Entera Bio Ltd. Ordinary Shares (ENTX) driven by superior Momentum & Technical, Options & Structure. Fundamentally, ENTX trades at N/M Forward P/E with 0.0% operating margin (-100.0% YoY revenue) versus CING at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ENTX sits in CONSOLIDATION (32nd %ile IV; Dealer Gamma Walls on Pro) against CING sits in BREAKDOWN (16th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
ENTX N/M vs CING N/M Fwd P/E
Growth & Margin Winner
Tie
Op Margin 0.0% vs 0.0% ยท YoY -100.0% vs +0.0%
Momentum & Technical Winner
ENTX
1Y +11.1% vs +35.4% ยท 52W Pos 64% vs 18%
Options & Structure Winner
ENTX
CONSOLIDATION (32nd %ile IV) vs BREAKDOWN (16th %ile IV)
ENTX
NASDAQ
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.01
-0.33% 1D
Market Cap
$541.6M
1M Return
+2.38%
1Y Return
+11.07%
Forward P/E
N/M
Unified AI Score
53.5 / 100
HOLD
Tech 35.0
Fund 55.0
Flow 72.0
Mom 60.0
CING
NASDAQ
Cingulate Inc. Common Stock
Pharmaceutical Preparations
$4.72
+26.0% 1D
Market Cap
$62.5M
1M Return
+8.37%
1Y Return
+35.39%
Forward P/E
N/M
Unified AI Score
44.8 / 100
HOLD
Tech 31.0
Fund 50.0
Flow 67.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ENTX +11.07%
CING +35.39%
Spread: +24.32 pp (CING Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
ENTX TTM Op. Margin: 0.0%
CING TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ENTX vs CING. Trailing 12-month operating profitability (ENTX 0.0% vs CING 0.0%) and valuation multiples (ENTX N/M vs CING N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ENTX | CING | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $541.6M | $62.5M | Larger Scale | ENTX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -100.0% | +0.0% | Higher Growth | CING |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -20.3% | -198.7% | Higher ROE | ENTX |
| 52-Week Range Position Momentum | 64% ($1โ$4) | 18% ($3โ$12) | Stronger Trend | ENTX |
| Beta / 30D Volatility Risk Regime | 1.07ฮฒ ยท 45% Vol | 1.07ฮฒ ยท 121% Vol | Lower Realized Risk | ENTX |
| Unified Institutional Score Composite Signal | 53.5 / 100 (HOLD) | 44.8 / 100 (HOLD) | Higher Composite | ENTX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ENTX vs CING Buy Guide
ENTX
CONSOLIDATION
80d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
32nd %ile
IV Regime
Balanced (25thโ60th %ile)
CING
BREAKDOWN
170d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
16th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ENTX nor CING registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.